Company Profile

Lancell LLC
Profile last edited on: 8/30/2023      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3550 General Atomics Court
San Diego, CA 92121
   (858) 455-3791
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Lancell is in the process of developing a molecular treatment that activates dendritic cells when applied topically to the skin over a vaccine injection site. The vaccine, combined with the Lancell treatment, activates strong, rapid T cell immunity and may also induce strong, rapid antibody protection that accelerates the vaccine's effectiveness. This treatment can be used with any type of current vaccine, as well as those that are under development (the much anticipated avian flu vaccine, for example).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 2 NIH $1,875,075
Project Title: Topical Adjuvants to Enhance the Efficacy of Influenza Vaccines
2003 2 NIH $922,266
Project Title: Transport Of Peptides To Epidermal Langerhans Cells

Key People / Management

  Carol O Cowing -- President

  Blake Millikin

Company News

There are no news available.